Gene therapy micro-cap Krystal Biotech prices upsized $40 million IPO at $10 midpoint – Nasdaq
|
Gene therapy micro-cap Krystal Biotech prices upsized $40 million IPO at $10 midpoint
Nasdaq Krystal Biotech, a preclinical gene therapy biotech focused on dermatological diseases, raised $40 million by offering 3.96 million shares at $10, at the midpoint of the $9 to $11 target range. Insiders had indicated an interest in purchasing up to $5 … Krystal Biotech boosts IPO share offering |
